Elanco Animal Health (NYSE:ELAN) Stock Rating Lowered by Wall Street Zen

Elanco Animal Health (NYSE:ELAN) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Sunday.

Several other analysts also recently weighed in on ELAN. Barclays assumed coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Stifel Nicolaus lifted their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Finally, KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.78.

Elanco Animal Health Stock Up 1.0%

NYSE:ELAN opened at $23.47 on Friday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $23.89. The company has a market cap of $11.66 billion, a PE ratio of 391.20, a P/E/G ratio of 3.26 and a beta of 1.87. The company’s 50 day moving average is $22.27 and its two-hundred day moving average is $19.32.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current year.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons bought 22,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Robert M. Vanhimbergen bought 6,950 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 43,450 shares of company stock worth $937,883 in the last quarter. 0.89% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ELAN. Wealth Enhancement Advisory Services LLC raised its position in shares of Elanco Animal Health by 71.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 27,857 shares of the company’s stock valued at $663,000 after buying an additional 11,580 shares during the last quarter. GAMMA Investing LLC lifted its stake in Elanco Animal Health by 34.1% in the 4th quarter. GAMMA Investing LLC now owns 11,691 shares of the company’s stock worth $265,000 after purchasing an additional 2,972 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Elanco Animal Health by 266.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after purchasing an additional 1,394,839 shares during the last quarter. New Mexico Educational Retirement Board purchased a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $1,998,000. Finally, CTC Alternative Strategies Ltd. acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $220,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.